Pancreatic Cancer Research

ResearcherKunming University of Science and TechnologyActive in the last 2 years

Yun Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7750-1370, 0000-0002-5758-5914; OpenAlex author ID A5102005132, A5113906223. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 2 papers

Papers 11

  1. Ellagic Acid Enhances RSL3-Induced Ferroptosis by Inhibiting the Nrf2/HO-1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1096/fj.202602231r↗
  2. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Co-author DOI 10.1158/0008-5472.can-26-0333↗
  3. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  4. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  5. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  6. Perineural invasion and the "cold" tumor microenvironment in pancreatic cancer: mechanisms of crosstalk and therapeutic opportunities. Co-author DOI 10.3389/fimmu.2025.1650117↗
  7. Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. Co-author DOI 10.3724/abbs.2023288↗
  8. MiR-135b-5p is an oncogene in pancreatic cancer to regulate GPRC5A expression by targeting transcription factor KLF4. First author DOI 10.1038/s41420-022-00814-y↗
  9. Is it justified to assess the resectability of pancreatic cancer combined with biological and conditional factors? Co-author DOI 10.21037/tcr-22-1258↗
  10. Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells. Co-author DOI 10.1002/bab.1657↗
  11. Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro. Co-author DOI 10.3892/ol.2018.8363↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ning Pu · 4 shared papers, 2025–2026 · strength 0.83
  2. Hanlin Yin · 4 shared papers, 2025–2026 · strength 0.83
  3. Qiangda Chen · 4 shared papers, 2025–2026 · strength 0.83
  4. Taochen He · 4 shared papers, 2025–2026 · strength 0.83
  5. Wenhui Lou · 4 shared papers, 2025–2026 · strength 0.83
  6. Wenchuan Wu · 3 shared papers, 2025–2026 · strength 0.64
  7. Wenquan Wang · 2 shared papers, 2024–2025 · strength 0.43
  8. Zhihang Xu · 2 shared papers, 2025 · strength 0.41
  9. Yaolin Xu · 2 shared papers, 2025 · strength 0.41
  10. Jiande Han · 2 shared papers, 2025 · strength 0.41
  11. Haibo Wang · 2 shared papers, 2025 · strength 0.41
  12. Jun Yu · 2 shared papers, 2025 · strength 0.41
  13. Pingping Hu · 1 shared paper, 2026 · strength 0.29
  14. Jianhua Bai · 1 shared paper, 2026 · strength 0.29
  15. Chern Ein Oon · 1 shared paper, 2026 · strength 0.29
  16. Lei Zou · 1 shared paper, 2025 · strength 0.28
  17. Jianbiao Xu · 1 shared paper, 2025 · strength 0.28
  18. Jinbin Jia · 1 shared paper, 2024 · strength 0.23
  19. Liang Liu · 1 shared paper, 2024 · strength 0.23
  20. Zheng Zhang · 1 shared paper, 2024 · strength 0.23
  21. Zijin Xu · 1 shared paper, 2024 · strength 0.23
  22. Chaoyu Pang · 1 shared paper, 2026 · strength 0.23
  23. Haibo Wang · 1 shared paper, 2026 · strength 0.23
  24. Yanfei An · 1 shared paper, 2026 · strength 0.23
  25. Liang Liu · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.